16 September 2025 : Clinical Research
Thoracic Radiation on Survival in Patients with Advanced Small Cell Lung Cancer Treated with Chemoimmunotherapy
Yunbin Gao ABG 1,2, Xuyu Zhang BCE 1, Dawei Zhao BEF 1, Jifeng Sun BDE 1, Lixia Zhang BCEF 3, Song Guan BDEF 3, Lujun Zhao AE 3*DOI: 10.12659/MSM.947713
Med Sci Monit 2025; 31:e947713
Figure 4 Subgroup analysis of progression-free survival (PFS) between thoracic radiotherapy (TRT) and non-TRT groups. Identification of the patients’ PFS in different subgroup is classified by age, oligometastases, brain metastases, bone metastases, liver metastases, and immunotherapy. Subgroups analyzed: age (<65 vs ≥65 years), oligometastases (Yes vs No), brain metastases (Yes vs No), bone metastases (Yes vs No), liver metastases (Yes vs No), response to immunotherapy (PR, SD, and PD). TRT – thoracic radiotherapy; HR – hazard ratio; OS – overall survival; PR – partial response; SD – stable disease; PD – progressive disease.